Accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) treated with STI-571 (Gleevec): Peripheral blood (PB) and bone marrow (BM) findings

被引：0
|
作者：
Frater, JL [1 ]
Tallman, MS [1 ]
Variakojis, D [1 ]
Boehlke, L [1 ]
Peterson, LC [1 ]
机构：
[1] Northwestern Univ, Sch Med, Chicago, IL USA
来源：
LABORATORY INVESTIGATION | 2002年 / 82卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1006
引用
收藏
页码：241A / 241A
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)
    T Fischer
    C Reifenrath
    GR Hess
    MT Corsetti
    S Kreil
    J Beck
    P Meinhardt
    G Beltrami
    B Schuch
    H Gschaidmeier
    R Hehlmann
    A Hochhaus
    A Carella
    C Huber
    Leukemia, 2002, 16 : 1220 - 1228
  • [32] Imatinib (STI571, Gleevec™) achieves prolonged survival in patients with accelerated phase Ph plus chronic myeloid leukemia (CML-AP):: Up to 36 months follow-up of a phase II study.
    Talpaz, M
    Silver, RT
    Druker, BJ
    Paquette, R
    Goldman, JM
    Gambacorti-Passerini, C
    Guilhot, F
    Schiffer, CA
    Fischer, T
    O'Brien, SG
    Deininger, MW
    Hochhaus, A
    Ottmann, OG
    Gratwohl, A
    Tura, S
    Baccarani, M
    Stone, RM
    Reiffers, J
    Bolton, AE
    Gathmann, I
    BLOOD, 2002, 100 (11) : 163A - 163A
  • [33] A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Larson, R.
    Weitzman, A.
    Haque, A.
    Giles, F.
    O'Brien, S. G.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Abnormal B Lymphoid Blasts May Not Always Indicate Accelerated or Blast Phase in Chronic Myelogenous Leukemia (CML)
    Soma, Lori
    Ding, Cheng
    Cherian, Sindhu
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (05) : 700 - 700
  • [35] ORAL IDARUBICIN IN THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA (AML) AND CHRONIC MYELOID-LEUKEMIA (CML) ACCELERATED PHASE BLAST CRISIS
    MALIK, STA
    TUCKER, J
    BRACE, W
    ROHATINER, AZS
    LISTER, TA
    BRITISH JOURNAL OF CANCER, 1988, 58 (02) : 277 - 277
  • [36] Hematologic, cytogenetic and molecular response to Glivec® (formerly STI571) in Ph+ chronic myeloid leukemia (CML) in accelerated and blastic phase (AP, BP):: A prospective study of the Italian cooperative study group on CML.
    Rosti, G
    Alberti, D
    De Vivo, A
    Bonifazi, F
    Trabacchi, E
    Bassi, S
    Vecchi, K
    Testoni, N
    Amabile, M
    Ottaviani, E
    Tiribelli, M
    Gottardi, E
    Cilloni, D
    Pane, F
    Intrieri, M
    Salvatore, F
    Martinelli, G
    Saglio, G
    Tura, S
    Baccarani, M
    BLOOD, 2001, 98 (11) : 138A - 138A
  • [37] Minimal residual disease (MRD) monitoring by quantitative RT-PCR (RQ PCR) and FISH in chronic myelogenous leukemia (CML) patients treated with STI571 (Gleevec®).
    Roche, C
    Grardel, N
    Cornu-Soenen, V
    Laï, JL
    Roumier, C
    Berthaud, P
    Chatelain, N
    Cosson, A
    Facon, T
    Preudhomme, C
    BLOOD, 2001, 98 (11) : 615A - 615A
  • [38] Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance
    Le Coutre, Philipp
    Giles, Francis J.
    Apperley, Jane
    Ottmann, Oliver G.
    Gattermann, Norbert
    O'Brien, Stephen G.
    Kuliczkowski, Kazimierz
    Larson, Richard A.
    Kim, Dong-Wook
    Haque, Ariful
    Gallagher, Neil
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 145A - 145A
  • [39] Gleevec™ (formerly STI571):: An active drug in patients with Ph plus chronic myeloid leukemia in accelerated phase -: Updated results of a phase II study.
    Talpaz, M
    Silver, RT
    Druker, B
    Paquette, R
    Goldman, JM
    Gambacorti-Passerini, C
    Guilhot, F
    Schiffer, CA
    Reese, SF
    Kantarjian, HM
    Ford, JM
    BLOOD, 2001, 98 (11) : 845A - 845A
  • [40] High dose cladribine (2CDA) therapy for chronic myelogenous leukemia in blast phase (CML-BP).
    Dann, EJ
    Anastasi, J
    Larson, RA
    BLOOD, 1996, 88 (10) : 928 - 928
12345